5 Contradicted by research
Nattokinase supplementation can help reduce LDL cholesterol levels.
"I decided to start supplementing with nattokinase, which can naturally help reduce LDL cholesterol." (said at 1:19:08)
A 2023 systematic review and meta-analysis of randomized controlled trials (6 RCTs, 546 participants) found that nattokinase supplementation alone does not reduce LDL cholesterol. In fact, lower doses showed a slight increase in LDL cholesterol compared to placebo (MD = 6.49 mg/dL, 95% CI: 0.83 to 12.15, p = 0.02), while higher doses showed no significant difference in LDL levels. While combination supplements containing nattokinase and red yeast rice (Monascus purpureus) significantly lower LDL cholesterol, clinical trials demonstrate that this effect is driven by the red yeast rice component (which naturally contains monacolin K / lovastatin), not nattokinase alone.
- contradicts: Combined nattokinase with red yeast rice but not nattokinase alone has potent effects on b… (Asia Pacific journal of clinical nutrition 2009) · cited 26x in the literature
"The mono formula showed no effects on blood lipids until month six, while the combined formula ameliorated all of measured lipids starting from month one... After controlling for baseline levels, only the combined group, but not mono group, showed a significant difference (p<0.0001) in TC, LDL-C and TC/HDL-C ratio when compared with the placebo group." (abstract, results)
pubmed - contradicts: Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-… (Reviews in cardiovascular medicine 2023) · cited 9x in the literature
"Relatively low total dosage of nattokinase had a negative effect on blood total cholesterol (MD [mean difference] = 5.27, 95% CI [confidence intervals]: 3.74 to 6.81, p < 0.00001), high-density lipoprotein cholesterol (MD = -2.76, 95% CI: -3.88 to -1.64, p < 0.00001), and low-density lipoprotein cholesterol (MD = 6.49, 95% CI: 0.83 to 12.15, p = 0.02)... Nattokinase group with relatively high total dosage also had a higher total cholesterol (MD = 3.18, 95% CI: 2.29 to 4.06, p < 0.00001) than control interventions, but no significant differences were found in levels of high-density lipoprotein cholesterol and low-density lipoprotein cholesterol." (abstract, results)
pubmedfull study (doi)
The thymus receives sympathetic and parasympathetic neural innervation that regulates its hormonal secretion.
"There's sympathetic and parasympathetic innervations for thymus um that dictates its hormonal output." (said at 1:32:14)
The claim asserts that the thymus receives both sympathetic and parasympathetic innervation that controls its hormonal output. While sympathetic (noradrenergic) innervation of the thymus is well established, neuroanatomical tracing and imaging studies have demonstrated that there is no verified parasympathetic (vagal) innervation of the thymic parenchyma (early reports suggesting vagal inputs were shown to result from tracer spread to adjacent cervical/esophageal structures). Because the claim bundles sympathetic and parasympathetic pathways, grading the least accurate part results in a contradicted verdict.
- contradicts: Autonomic innervation and regulation of the immune system (1987-2007). (Brain, behavior, and immunity 2007) · cited 861x in the literature
"These studies demonstrated that all primary and secondary immune organs receive a substantial sympathetic innervation from sympathetic postganglionic neurons. Neither the thymus nor spleen receive any sensory neural innervation... There is no neuroanatomical evidence for a parasympathetic or vagal nerve supply to any immune organ." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Re-investigation of the innervation of the thymus gland in mice and rats. (Brain, behavior, and immunity 1987) · cited 105x in the literature
"Unilateral vagotomy did not alter cholinesterase activity in the thymus even though it was largely depleted in the ipsilateral nucleus ambiguus. The histochemical studies verified a major sympathetic innervation of the thymus gland... In summary, all labeled cells in the brain stem and cervical spinal cord observed following tracer injections into the thymus can be accounted for by spread of the tracer into surrounding structures, leading to spurious labeling." (abstract, results, passage verified)
pubmedfull study (doi) - partial: 3D anatomy of autonomic innervations in immune organs of a non-human primate and the human… (Fundamental research 2023) · cited 8x in the literature
"On the other hand, only sparse, if any, sympathetic inputs were observed inside the lymph nodes, Peyer's patches, or thymus. In contrast, there were minimal parasympathetic innervations in the parenchyma of these examined immune organs." (abstract, results, passage verified)
pubmedfull study (doi)
Thymosin alpha-1 was previously FDA-approved under the brand name Zadaxin for conditions involving thymic abnormalities like DiGeorge syndrome.
"It was FDA approved as Zadaxin um for kids that were born without a thymus or a malfunctioning thymus like DiGeorge syndrome, these different kind of genetic abnormalities, um to be used for these kids to help develop the T cells that they had that weren't in the thymus" (said at 1:37:25)
Thymosin alpha-1 (marketed by SciClone Pharmaceuticals under the brand name Zadaxin) has never received FDA marketing approval for DiGeorge syndrome or any other medical condition in the United States. Although thymosin alpha-1 was investigated as an orphan drug candidate for DiGeorge syndrome and evaluated in US clinical trials for chronic hepatitis B and C, and is approved in over 30 countries outside the US (primarily for viral hepatitis and as an immune adjuvant), it was never approved by the US FDA.
- contradicts: Thymosin alpha-1. (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2001) · cited 35x in the literature
"The drug is in Phase III trials for the treatment of hepatitis C and in Phase II trials for hepatitis B. Additional possible indications are malignant melanoma, hepatocellular carcinoma, drug-resistant tuberculosis, and DiGeorge's syndrome." (abstract, passage verified)
pubmedfull study (doi) - contradicts: Thymosin alpha1. SciClone Pharmaceuticals. (Current opinion in investigational drugs (London, England : 2000) 2002) · cited 64x in the literature
"By July 2001, it was in phase III trials in the US in combination with PEGylated interferon-alpha, and later the same month it was approved in the Philippines. SciClone received expanded approval for HBV and HCV infection in Mexico in July 2001. Talpha1 has been launched in Argentina, China, Peru, the Philippines and Singapore for the treatment of chronic HBV infection." (abstract, passage verified)
pubmed
GLP-1 receptors are present on POMC neurons in the brain.
"There's GLP-1 receptors on the POMC neurons in the brain, and no one's kind of examined what that means." (said at 2:31:15)
The spoken statement contains two assertions. First, the assertion that GLP-1 receptors are present on POMC neurons in the brain is supported: rodent and cellular studies confirm that proopiomelanocortin (POMC) neurons in the hypothalamic arcuate nucleus express functional GLP-1 receptors (GLP-1Rs). However, the bundled assertion that 'no one's kind of examined what that means' is contradicted by extensive published literature. Seminal electrophysiological and pharmacological studies (e.g., Secher et al., 2014; He et al., 2019; Farkas et al., 2021) have directly investigated the functional consequences of GLP-1R activation on POMC neurons, demonstrating direct depolarization, activation via TrpC5 channels, enhanced excitatory tone, and mediation of GLP-1 receptor agonist-induced appetite suppression and weight loss.
Retatrutide has fewer gastrointestinal side effects compared to earlier GLP-1 agonists.
"retatrutide even have less of these gastrointestinal effects" (said at 2:33:45)
Clinical trial data and network meta-analyses do not support the claim that retatrutide causes fewer gastrointestinal (GI) adverse effects than earlier GLP-1 receptor agonists. Phase 2 and Phase 3 randomized trials demonstrate that GI symptoms (such as nausea, vomiting, diarrhea, and constipation) remain the most common adverse events associated with retatrutide, occurring in a dose-dependent pattern with a safety profile consistent with the broader GLP-1 and incretin-based receptor agonist class.
- contradicts: Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. (The New England journal of medicine 2023) · cited 1059x in the literature
"The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg)." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic R… (Cardiology in review 2026)
"However, the use of dual and triple agonists was associated with a higher risk of any adverse events (AEs) (RR 1.13; 95% CI: 1.08-1.19), including gastrointestinal AEs (nausea, vomiting, diarrhea, constipation), AEs leading to withdrawal (RR 1.96; 95% CI: 1.17-3.30)" (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people… (Lancet (London, England) 2026) · cited 8x in the literature
"The most frequent adverse events with retatrutide were generally mild to moderate gastrointestinal events, which subsided over time... with an adverse event profile consistent with molecules with GLP-1 agonist activity" (abstract, results and conclusions)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.